Does #baricitinib affect #fatigue in RA patients? 👉🏼Results from RA-BEAM and RA-BEACON 👉🏼4mg baricitinib significantly reduced fatigue, starting week 16, compared to placebo 👉🏼Effect independent of disease activity in active RA Abs#1235 #ACR21 @RheumNow https://t.co/0SKhUKJHd7 https://t.co/R76wc56u6I

• Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two…

Go @utmbhealth! Final Round Knowledge Bowl #ACR21 @RheumNow @UTMBInternalMed #DanielGonzalez #AparnaDas https://t.co/nQRn3s7J21

Abst 1550 #acr21 @RheumNow @bryan_neel rheum pts after covid 19 vaccine: 18.9% reported SEs after the 1st dose,33.1% after 2nd dose. most frequent SEs fever, HA, fatigue & arthromyalgia. All mild&self resolved. Disease flare in 1/180 pts (0.6%) 1st dose 4/118 (3.4%) 2nd dose https://t.co/5AB5CJfYt8

Do you use #septa in #renal #lupus if on high dose prednisone? @RheumNow #ACR21 8M212 lupus hub

After that fantastic Plenary III, we need a well-deserved timeout and time for stretching 🙆🏻‍♂️ 🙆‍♀️! #wellness #ACR21 #RheumPix #RheumNow https://t.co/krF5tPAxsE

#ACR21 Knowledge Bowl - Enjoy the farmer's market! --> Cauliflower ears, cherries for gout, alfalfa and SLE... and of course anti-OJ myositis @Rheumnow https://t.co/K8aG1IKYCu

#SLE study hub re #Lupus nephritis rocks. #Rituximab ⬇️antiDNA but then rebound ⤴️. Thus design of adding #belimumab to Rituximab=Less flares. Love the Hubs. #ACR21 @RheumNow https://t.co/MAhxJdmkWO 10.7326/M21-2078 #ACRBest https://t.co/qWPk5x1ZtM

• https://www.acpjournals.org/doi/

Younger age, male gender, geographic region, lower weight and BMI, dactylitis+ or enthesitis+, lower scores Pt-Pain, PtGA, TJC and HAQ-DI were baseline predictors for achieving MDA and DAPSA LDA at Week 56 in UPA treated patients @RheumNow #ACR21 Abst#1348 https://t.co/FSXarBoBM1 https://t.co/UMCjr6eCRm

• Predictors for Achievement of Low Disease Activity at Week 56 in Patients with …

#ACR21 Ab#1029 - Great poster by Dr. Guttmann, IRAD in Summit NJ: ▶️2019 EULAR/ACR SLE criteria vs to 1997 ACR & SLICC ⭐️64% SLE pts: all 3 criteria. 10% only SLICC, 3% '97 ACR, 2% EULAR/ACR ⭐️Simliar gender, racial disparities to prior criteria @Rheumnow https://t.co/QzG78HJgw5 https://t.co/eyuYhj4Acf

• https://bit.ly/3H5DIqc

Almost like real-life, I've "run across the conference centre" to catch the end of the #InterstitialLungDisease session- some excellent insights from Dr Melissa Griffith on a complex topic, will definitely be reviewing the full talk later. #ACR21 @RheumNow https://t.co/LdhXI8LLqY

#ACR21 Abst#1029 @Rheumnow https://t.co/QzG78HJgw5 What is your preferred SLE classification criteria?

• https://bit.ly/3H5DIqc

#ILD in #rheumatic diseases. When to use #glucocorticoids and immune suppressive sand anti fibrotic. V clear but harder in real world! @RheumNow #ACR21 #ACRBest https://t.co/R4V5ZggRsu

• Jilaine Bolek Berquist on Twitter: "Live at #ACR21 
Love this treatmen…

Steroids can cause co-morbidities which increase CV risk, but can PNL directly increase CV event (MACE) risk in RA? 30d PNL➡️15% increase in MACE in next 30d (independent of underlying CV risk, RA dx activity) PNL actively confers risk! @BethIWallace #ACR21 ABST1428 @RheumNow https://t.co/cuL69n7cx3

#ACR21 Abs:#1429: ALPN-303: Dual BAFF/APRIL antagonist for SLE: ⭐️Encouraging immunomodulatory activity and efficacy in animal models. ⬇️ Plasma cells and Ig secretions in vitro & vivo ⭐️Well-tolerated in animals w/o adverse events 🔥Phase 1 study in healthy volunteers! @Rheumnow